InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection FR BL Cohort

NCT04407689 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

34

Enrollment

INDUSTRY

Sponsor class

Stopped poor accrual

Conditions

COVID-19
Lymphocytopenia

Interventions

DRUG: Interleukin-7
DRUG: Placebo

Sponsor

Revimmune

Collaborators

[object Object]
[object Object]